Augustine Therapeutics

Gaston Geenslaan 1

3001 Leuven

BE

Augustine Therapeutics

Foundation date

12/03/2019

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

Augustine Therapeutics focuses on the development of new medicines to treat severe debilitating diseases with high unmet need, in particular Charcot-Marie-Tooth disease (CMT) as well as other peripheral neuropathies. Augustine Therapeutics completed a seed financing round of €4.2 million in December 2019 with the support of VIB, V-Bio Ventures and PMV joined by Advent France Biotechnology and the Gemma Frisius Fund. Augustine Therapeutics is a drug discovery company building a portfolio of first-in-class drugs rooted in the ground-breaking research on neurodegenerative disorders of Prof. Ludo Van Den Bosch, Prof. Joris De Wit and Prof. Bart De Strooper at VIB.

Upcoming events

Latest news

  • Mithra reaches milestone in estetrol skin study

    Tuesday April 9th 2024

  • Stool transplant shows promise for Parkinson's disease

    Thursday April 4th 2024

  • Strong data from Sequana Medical's DSR® proof-of-concept studies in heart failure published in European Journal of Heart Failure

    Wednesday April 3rd 2024